DiaSorin names IR chief as DiaSorin stock costs EUR 75.95

Published on 10/08/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Half-year revenue reached EUR 602 million, flat at constant rates. DiaSorin stock costs EUR 75.95 on October 8, 2026 after EUR 76.71, minus 0.99 percent.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin (ISIN IT0003492391) was trading at EUR 75.95 at Lang & Schwarz on October 8, 2026 at 1:47 p.m. CEST, down 0.99 percent versus the prior close of EUR 76.71. The company had appointed Margherita Sacerdoti investor relations and ESG senior director on October 2, 2026, according to DiaSorin.

Three milestones carry the story

On July 31, 2026, DiaSorin reported first-half revenue of EUR 602 million, flat year over year at constant exchange rates, while second-quarter revenue grew 4.00 percent at constant exchange rates, according to Yahoo Finance. On September 11, 2026, Morgan Stanley raised its DiaSorin price target to EUR 71.00 from EUR 65.00 while keeping an Equal Weight rating, as Markets Insider reported on September 11, 2026. On October 2, 2026, DiaSorin announced the investor relations appointment, while its full-year 2026 revenue-growth guidance remained 5.00 percent to 6.00 percent at constant exchange rates, according to DiaSorin.

What does the update mean for margins?

The operating picture improved during the second quarter. DiaSorin said adjusted earnings before interest, taxes, depreciation and amortization reached a 33.00 percent margin in the quarter, compared with 31.00 percent in the first quarter, while the first-half margin was 32.00 percent, according to Yahoo Finance. Management kept its full-year adjusted EBITDA margin guidance at 32.00 percent to 33.00 percent.

The comparison matters because first-half adjusted EBITDA was EUR 194 million, down 7.00 percent at constant exchange rates, even as the second-quarter revenue trend turned positive. China remained a counter-factor, with business declining about 25.00 percent in the second quarter, while DiaSorin said the United States and Europe were normalizing. The company also confirmed an objective of reaching 600 hospitals by the end of 2026, according to Yahoo Finance.

Next results date is November 5

The next dated event listed for DiaSorin is November 5, 2026, when the company is expected to report its next earnings, according to InvestPane. That report will show whether the 4.00 percent second-quarter revenue growth can continue into the second half and support the 32.00 percent to 33.00 percent full-year margin guide.

DiaSorin stock stays below its yearly high

DiaSorin stock was trading at EUR 75.95 at Lang & Schwarz on October 8, 2026 at 1:47 p.m. CEST, versus the EUR 76.71 prior close, while the 52-week range stood at EUR 52.34 to EUR 79.72. Its market capitalization was EUR 3.8 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.